[Ultra-high dose thrombolytic therapy with streptokinase in peripheral venous thrombosis]. / Ultrahochdosierte Thrombolysetherapie mit Streptokinase bei peripherer Phlebothrombose.

56 patients with deep vein thrombosis (lower limb) and two patients with vena subclavia thrombosis were treated for six hours/day according to an ultrahigh dosage scheme (1,500,000 U/h streptokinase). An average number of three cycles was applied. Complete recanalization could be demonstrated in 23 patients (43%) with lower limb thrombosis, whereas a partial recanalization was demonstrable in 40% (22 patients). A complete thrombolysis could be achieved in one patient with vena subclavia thrombosis. Severe side effects were one intracerebral hemorrhage and one major lung embolism, causing death in both patients. Ultrahigh dosage thrombolysis with streptokinase is an effective therapeutic regimen and is considered to be an alternative to standard fibrinolytic procedures.

In vitro IgE-secretion in atopic eczema: influence of allergens and mitogens and role of CD8 T cell subpopulation.

In cultures of peripheral blood mononuclear cells (PBMC) from 23 atopic patients and 14 controls the influence of mitogens, allergens and CD8 suppressor T lymphocytes on the in vitro IgE response was studied. The in vitro IgE levels in lymphocyte culture supernatants reached a plateau after 6 days of culture, whereby low levels of IgE could be reproducibly measured down to 0.5 ng/ml. The spontaneous in vitro IgE secretion from PBMC of atopic eczema patients was elevated in comparison to the control group and showed a direct correlation (r = 0.72) to the serum IgE levels. Pokeweed mitogen rather suppressed the in vitro IgE production. After removal of the CD8 subpopulation of T lymphocytes by using an indirect erythrocytes rosetting technique we found increased in vitro levels pointing to a role of IgE regulating T suppressor subpopulations.